$5.90
0.16% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US74019L1070
Symbol
PRPO
Sector
Industry

Precipio, Inc. Stock News

Neutral
Seeking Alpha
8 days ago
Precipio, Inc. (NASDAQ:PRPO ) Q3 2024 Earnings Conference Call November 18, 2024 5:00 PM ET Company Participants Ilan Danieli - CEO Conference Call Participants Operator Good day. Welcome to the Precipio Third Quarter 2024 Shareholder Update Conference Call.
Neutral
GlobeNewsWire
20 days ago
NEW HAVEN, Conn., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q3-2024 corporate update call on November 18th at 5:00 PM ET. The call will provide commentary on Precipio's Q3-2024 10-Q filed today, including financial highlights and analysis of the company's core businesses.
Neutral
GlobeNewsWire
about 2 months ago
The unique assay enables laboratories to provide clinicians with more informed treatment decisions for their patients The unique assay enables laboratories to provide clinicians with more informed treatment decisions for their patients
Neutral
GlobeNewsWire
3 months ago
NEW HAVEN, Conn., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company  Precipio, Inc.   (NASDAQ: PRPO) announces the Company's repricing of a portion of its employee stock options to ensure their effectiveness as a retention tool for valuable employees.
Neutral
Seeking Alpha
3 months ago
Precipio, Inc. (NASDAQ:PRPO ) Q2 2024 Earnings Conference Call August 19, 2024 5:00 PM ET Company Participants Ilan Danieli - Chief Executive Officer Operator Welcome to the Precipio Second Quarter 2024 Shareholder Update Conference Call. All participants will be in a listen-only mode.
Neutral
GlobeNewsWire
3 months ago
NEW HAVEN, Conn., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company  Precipio, Inc.   (NASDAQ: PRPO) , will be hosting its Q2-2024 corporate update call on August 19th at 5:00 PM ET.
Neutral
GlobeNewsWire
4 months ago
Company's continued growth and improved cash position alleviates the need for capital raise in the foreseeable future Company's continued growth and improved cash position alleviates the need for capital raise in the foreseeable future
Neutral
GlobeNewsWire
4 months ago
Pathology Revenues in June exceed breakeven target and continue growth trend Pathology Revenues in June exceed breakeven target and continue growth trend

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today